UB Paderborn / Katalog / Suche / in CDI

LBA2_PR Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S152-S153

2016

Volltextzugriff (PDF)

LBA1_PR Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S152-S152

2016

Volltextzugriff (PDF)

Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)

Annals of oncology, 2014-09, Vol.25, p.iv152

2014

Volltextzugriff (PDF)

16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

European journal of cancer (1990), 2015-09, Vol.51, p.S717-S718

2015

Volltextzugriff (PDF)

Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer

Annals of oncology, 2018-09, Vol.29 (9), p.1980-1986

2018

Volltextzugriff (PDF)

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

Annals of oncology, 2009-02, Vol.20 (2), p.298-304

2009

Volltextzugriff (PDF)

Breakthroughs in Basic Research

Annals of oncology, 2012-09, Vol.23, p.ix51-ix52

Janne, P.A.

2012

Volltextzugriff (PDF)

84IN - Breakthroughs in Basic Research

Annals of oncology, 2012-09, Vol.23, p.ix51-ix52

Janne, P.A.

2012

Volltextzugriff (PDF)

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

Annals of oncology, 2008-04, Vol.19 (4), p.717-723

2008

Volltextzugriff (PDF)

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium

Annals of oncology, 2019-04, Vol.30 (4), p.597-603

2019

Volltextzugriff (PDF)

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

European journal of cancer (1990), 2020-10, Vol.138, p.S1-S2

2020

Volltextzugriff (PDF)

Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study

ESMO open, 2021-10, Vol.6 (5), p.100271-100271, Article 100271

2021

Volltextzugriff (PDF)

Gene Translocations as Targets for Treatment

Annals of oncology, 2013-03, Vol.24, p.i7-i7

Janne, P.A.

2013

Volltextzugriff (PDF)

Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells

Oncogene, 2015-04, Vol.34 (17), p.2167-2177

2015

Volltextzugriff (PDF)

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma

Annals of oncology, 2023-07, Vol.34 (7), p.589-604

2023

Volltextzugriff (PDF)

MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S175

2023

Volltextzugriff (PDF)

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

Oncogene, 2016-02, Vol.35 (7), p.878-886

2016

Volltextzugriff (PDF)

14MO Updated efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC)

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S47-S48

2023

Volltextzugriff (PDF)

1231P Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy

Annals of oncology, 2021-09, Vol.32, p.S975-S975

2021

Volltextzugriff (PDF)

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Oncogene, 2010-04, Vol.29 (16), p.2346-2356

2010

Volltextzugriff (PDF)

OA01.07 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations

Journal of thoracic oncology, 2023-03, Vol.18 (3), p.e3-e3

2023

Volltextzugriff (PDF)

Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy

Clinical radiology, 2014-08, Vol.69 (8), p.841-848

2014

Volltextzugriff (PDF)

1218P Characterization of GI toxicities and their impact on efficacy in patients (pts) with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) treated with mobocertinib (TAK-788) who previously received platinum chemotherapy

Annals of oncology, 2021-09, Vol.32, p.S968-S969

2021

Volltextzugriff (PDF)

Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC

Annals of oncology, 2018-10, Vol.29, p.viii545-viii546

2018

Volltextzugriff (PDF)

552 POSTER Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design

European journal of cancer supplements, 2008, Vol.6 (12), p.174-174

2008

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

LBA2_PR Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results

LBA1_PR Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)

16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

Breakthroughs in Basic Research

84IN - Breakthroughs in Basic Research

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study

Gene Translocations as Targets for Treatment

Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma

MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

14MO Updated efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC)

1231P Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

OA01.07 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations

Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy

1218P Characterization of GI toxicities and their impact on efficacy in patients (pts) with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) treated with mobocertinib (TAK-788) who previously received platinum chemotherapy

Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC

552 POSTER Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design

Suchergebnisse filtern